Rastetter H. William's Insider Trades & SAST Disclosures
Rastetter H. William's most recent trade in Neurocrine Biosciences, Inc. was a trade of 14,250 Common Stock done at an average price of $146.7 . Disclosure was reported to the exchange on Aug. 15, 2024.
Add Superstar Alert
Note
This is a custom search result for pattern Rastetter H. William.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Sale of securities on an exchange or to another person at price $ 146.69 per share. | 15 Aug 2024 | 14,250 | 37,491 (0%) | 0% | 146.7 | 2,090,333 | Common Stock |
|
Fate Therapeutics Inc
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
|
Dare Bioscience Inc
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 2,869 | 2,869 | - | - | Restricted Stock Unit | |
|
Regulus Therapeutics Inc
Board Meeting |
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
|
Regulus Therapeutics Inc
Board Meeting |
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
|
Neurocrine Biosciences, Inc.
|
William Rastetter H. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.98 per share. | 02 Jan 2024 | 20,000 | 62,785 (0%) | 0% | 13.0 | 259,600 | Common Stock |
|
Neurocrine Biosciences, Inc.
|
Rastetter H. William | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 20,000 | 0 | - | - | Non-Qualified Stock Option | |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Sale of securities on an exchange or to another person at price $ 131.47 per share. | 02 Jan 2024 | 11,044 | 51,741 (0%) | 0% | 131.5 | 1,451,927 | Common Stock |
|
Regulus Therapeutics Inc
Board Meeting |
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
|
Dare Bioscience Inc
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
|
Regulus Therapeutics Inc
Board Meeting |
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
|
Fate Therapeutics Inc
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 8,579 | 8,579 | - | - | Non-Qualified Stock Option | |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 7,625 | 0 | - | - | Non-Qualified Stock Option | |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.71 per share. | 01 May 2023 | 7,625 | 47,085 (0%) | 0% | 12.7 | 96,914 | Common Stock |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Sale of securities on an exchange or to another person at price $ 101.43 per share. | 01 May 2023 | 4,300 | 42,785 (0%) | 0% | 101.4 | 436,135 | Common Stock |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.71 per share. | 19 Apr 2023 | 10,765 | 45,494 (0%) | 0% | 12.7 | 136,823 | Common Stock |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2023 | 10,765 | 7,625 | - | - | Non-Qualified Stock Option | |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Sale of securities on an exchange or to another person at price $ 105.04 per share. | 19 Apr 2023 | 6,034 | 39,460 (0%) | 0% | 105.0 | 633,787 | Common Stock |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.71 per share. | 19 Apr 2023 | 1,610 | 35,632 (0%) | 0% | 12.7 | 20,463 | Common Stock |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2023 | 1,610 | 18,390 | - | - | Non-Qualified Stock Option | |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Sale of securities on an exchange or to another person at price $ 105.00 per share. | 19 Apr 2023 | 903 | 34,729 (0%) | 0% | 105.0 | 94,819 | Common Stock |
|
Fate Therapeutics Inc
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 11,893 | 11,893 | - | - | Stock Option (Right to Buy) | |
|
Fate Therapeutics Inc
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 8,650 | 11,331 (0%) | 0% | 0 | Common Stock | |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 9,724 | 9,724 | - | - | Non-Qualified Stock Option | |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 20,000 | 0 | - | - | Non-Qualified Stock Option | |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.66 per share. | 01 Apr 2022 | 20,000 | 44,750 (0%) | 0% | 6.7 | 133,200 | Common Stock |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Sale of securities on an exchange or to another person at price $ 94.93 per share. | 01 Apr 2022 | 10,728 | 34,022 (0%) | 0% | 94.9 | 1,018,366 | Common Stock |
|
Dare Bioscience Inc
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
|
Fate Therapeutics Inc
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 4,334 | 4,334 | - | - | Stock Option (Right to Buy) | |
|
Fate Therapeutics Inc
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 2,681 | 2,681 (0%) | 0% | 0 | Common Stock | |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 8,833 | 8,833 | - | - | Non-Qualified Stock Option | |
|
Dare Bioscience Inc
|
William H. Rastetter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 22,500 | 22,500 | - | - | Stock Option (right to buy) | |
|
Neurocrine Biosciences, Inc.
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2020 | 6,018 | 6,018 | - | - | Non-Qualified Stock Option | |
|
Fate Therapeutics Inc
|
William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2020 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
|
Fate Therapeutics Inc
|
William H. Rastetter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2020 | 28,461 | 0 | - | - | Stock Option (right to buy) | |
|
Fate Therapeutics Inc
|
William H. Rastetter | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.37 per share. | 30 Mar 2020 | 28,461 | 28,461 (0%) | - | 1.4 | 38,992 | Common stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges